Addus HomeCare (NASDAQ:ADUS) Raised to Strong-Buy at Wall Street Zen

Addus HomeCare (NASDAQ:ADUS) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other brokerages have also recently weighed in on ADUS. TD Cowen boosted their price objective on Addus HomeCare from $131.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday. Royal Bank Of Canada raised their target price on shares of Addus HomeCare from $130.00 to $134.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Weiss Ratings raised shares of Addus HomeCare from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Raymond James Financial set a $137.00 price target on shares of Addus HomeCare in a research report on Monday, September 28th. Finally, Truist Financial boosted their price target on shares of Addus HomeCare from $135.00 to $148.00 and gave the stock a “buy” rating in a research note on Thursday. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $134.70.

Addus HomeCare Stock Performance

ADUS stock opened at $124.31 on Friday. The company has a market cap of $2.32 billion, a P/E ratio of 20.72, a PEG ratio of 1.65 and a beta of 0.75. Addus HomeCare has a twelve month low of $87.95 and a twelve month high of $131.59. The company has a quick ratio of 1.64, a current ratio of 1.64 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $117.60 and a 200-day moving average of $106.88.

Addus HomeCare (NASDAQ:ADUS) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. The business had revenue of $387.74 million for the quarter, compared to analyst estimates of $388.72 million. Addus HomeCare had a return on equity of 10.22% and a net margin of 7.39%. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.56 earnings per share. As a group, equities research analysts expect that Addus HomeCare will post 6.34 EPS for the current year.

Institutional Investors Weigh In On Addus HomeCare

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Addus HomeCare during the second quarter worth about $344,153,000. Bank of America Corp DE acquired a new position in shares of Addus HomeCare during the 2nd quarter worth about $35,527,000. TimesSquare Capital Management LLC acquired a new position in shares of Addus HomeCare during the 2nd quarter worth about $31,502,000. Punch & Associates Investment Management Inc. acquired a new position in shares of Addus HomeCare during the 2nd quarter worth about $20,911,000. Finally, William Blair Investment Management LLC acquired a new position in shares of Addus HomeCare during the 2nd quarter worth about $17,703,000. Institutional investors own 95.35% of the company’s stock.

Key Stories Impacting Addus HomeCare

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: UBS raised its price target to $160 from $145 and maintained a Buy rating; TD Cowen lifted its target to $145 from $131 and also maintained a Buy rating. UBS price-target report TD Cowen price-target report
• Positive Sentiment: ADUS recently reached a 52-week high. Its latest quarterly results included earnings per share of $1.83, ahead of the $1.79 consensus, while revenue increased 7% year over year. Addus hits a 12-month high
• Positive Sentiment: The company said it expects to close its AccentCare acquisition in the first quarter of 2027 and anticipates a full-year adjusted EBITDA margin around 13%; the deal may offer a growth opportunity, though execution remains ahead. AccentCare update
• Neutral Sentiment: Recent Zacks pieces discuss ADUS’s momentum and value-investing appeal, but the available summaries do not provide specific ratings or new estimates. Zacks momentum article Zacks value article
• Negative Sentiment: Quarterly revenue of $387.74 million was slightly below analysts’ $388.72 million estimate, tempering the otherwise positive earnings beat. Q3 earnings call highlights

Addus HomeCare Company Profile

Addus HomeCare Inc (NASDAQ: ADUS) provides in-home personal care, hospice and home health services to older adults, people with disabilities and other individuals who need assistance with daily living or medical care. Its services are designed to help clients remain safely and independently in their homes while supporting families and caregivers.

The company’s personal care services include assistance with bathing, dressing, grooming, meal preparation, housekeeping and other activities of daily living.